echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > A review of Blood highlights!

    A review of Blood highlights!

    • Last Update: 2021-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    On June 3, Reindeer Medical and Cinda Biosciences jointly announced that the fully human BCMA CAR-T cell injection (CT103A, IBI326) jointly developed by the two companies for the treatment of relapsed/refractory multiple myeloma (R/R MM) The preliminary results of the Phase 1 clinical study were officially published in Blood, a top academic journal in the field of blood.


    Public information shows that CT103A uses lentivirus as a gene vector to transfect autologous T cells.


    The publication of Blood magazine is a clinical study on the treatment of R/R MM in China, which was conducted in the Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology.


    1) In terms of effectiveness, the objective response rate (ORR) of 18 subjects was 100%, and the complete response (CR)/strictly complete response (sCR) was 72.


    In addition, subjects who have previously received murine BCMA CAR-T treatment can still benefit from CT103A.


    2) In terms of safety, immune effector cell-related neurotoxicity syndrome (ICANS) was not observed in all dose groups.


    3) In terms of CAR-T cell expansion, digital PCR technology was used to detect, and the results showed that CAR-T cell expansion reached a peak at a median time of 12 days after reinfusion, and there was no significant difference in the PK parameters of each dose group.


    4) In terms of immunogenicity, the level of anti-drug antibody (ADA) of 18 subjects was tested, and only 1 subject was observed to be positive.


    Why did this research arouse the high attention of Blood magazine? The review articles of three experts Lydia Sarah, Hui Lee and Kwee L.


    The first is that CT103A has an eye-catching persistence in clinical practice.


    "We have seen that although the maximum concentration of circulating CT103A is lower than that reported by other CAR-T therapies, the median duration it brings to the follow-up period is 308 days, and this result may follow up later We have observed a strong expansion of T cells in all subjects.


    The second is that CT103A has a relatively low binding affinity.


    The third is to include subjects who have previously received murine BCMA CAR-T treatment for relapse.


    Note: The original text has been deleted

    Reference materials:

    Reference materials:

    [1] The research results of the holistic BCMA CAR-T therapy jointly developed by Cinda Biology and Reindeer Medical have been reviewed in the “Blood” journal of the American Society of Hematology.


    [1] The research results of the holistic BCMA CAR-T therapy jointly developed by Cinda Biology and Reindeer Medical have been reviewed in the “Blood” journal of the American Society of Hematology.


    [2]A Phase 1 Study of a Novel Fully Human BCMA-targeting CAR (CT103A) in Patients with Relapsed/Refractory Multiple Myeloma.


    [3] Lee LSH, Yong KL.
    BCMA CARs in multiple myeloma: room for more?.
    2021.

    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.